Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,421.89 +178.34 (+0.28%) CMC Crypto 200
1,351.91 -8.41 (-0.62%)
VERV Nov 2024 12.500 call
| Previous close | 0.1500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 12.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.1500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 51 |
Simply Wall St.One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
Viewing insider transactions for Verve Therapeutics, Inc.'s ( NASDAQ:VERV ) over the last year, we see that insiders...
GlobeNewswireVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c
- GlobeNewswire
Verve Therapeutics Announces Leadership Update
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Troy Lister, Ph.D., currently serving as Verve’s senior vice president, research and early development, has been appoint
